

## Special Issue

# Novel Targeted Cancer Therapeutics and Personalized Medicine

### Message from the Guest Editors

Although there has been continuous improvement in the survival and other outcomes of patients with cancer over time, cancer patients still have high mortality rates.

Moreover, thus far scientists have striven to develop a novel therapy based on the characteristics of numerous cancers. For instance, recent research revealed elevated immune system activity through immune checkpoint-related therapy as a novel targeted therapeutic to cure cancers. Furthermore, recent studies have indicated distinct features and heterogeneity of tumors through high throughput sequencing and mass spectrometry analysis. Therefore, it is critical to identify novel targets for cancer therapeutics and develop personalized medicine that can be used in the treatment of cancer patients.

Moreover, aiming at the treatment of molecular and cellular variability under different individual cancer patients is a new direction for cancer research. In this Special Issue, the current findings, as well as future research directions on the role of novel targets, mechanisms, and specific genes of cancers will be discussed.

---

### Guest Editors

Dr. Wei-Jan Wang

Research Center for Cancer Biology, Department of Biological Science and Technology, China Medical University, Taichung 40604, Taiwan

Dr. Chih-Yang Wang

College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan

---

### Deadline for manuscript submissions

closed (31 December 2022)



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/103899](https://mdpi.com/si/103899)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine* is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).